REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
389.83
-5.39 (-1.36%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close395.22
Open396.58
Bid360.01 x 800
Ask404.00 x 1100
Day's Range387.52 - 400.00
52 Week Range281.89 - 437.90
Volume597,393
Avg. Volume683,046
Market Cap42.08B
Beta (3Y Monthly)1.72
PE Ratio (TTM)28.30
EPS (TTM)13.77
Earnings DateNov 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est408.33
Trade prices are not sourced from all markets
  • Drugmakers are finding new solutions to food allergies
    CNBC Videos19 days ago

    Drugmakers are finding new solutions to food allergies

    CNBC's Meg Tirrell reports on what some drug companies are doing to fight increasing rates of food allergies in children.

  • Reutersyesterday

    Sanofi drug Dupixent wins U.S. FDA approval to treat asthma

    France's Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma. Dupixent, co-developed with U.S.-based Regeneron, received approval to treat patients with eosinophilic asthma and those dependent on anti-inflammatory steroids. The drug, a key revenue driver for Sanofi, had worldwide sales of 176 million euros ($202.5 million) in the second quarter of 2018, of which 151 million euros came from the United States.

  • GlobeNewswireyesterday

    Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)

    FDA approves asthma indication for Dupixent ® (dupilumab) Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype Only biologic approved for oral corticosteroid-dependent ...

  • PR Newswireyesterday

    FDA approves asthsma indication for Dupixent® (dupilumab)

    -- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype -- Only biologic approved for oral corticosteroid-dependent asthma, regardless of phenotype -- Only asthma ...

  • PR Newswireyesterday

    FDA Approves Asthma Indication for Dupixent® (dupilumab)

    Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced the U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

  • Regeneron and Alnylam Collaborate for NASH Research Program
    Market Realist2 days ago

    Regeneron and Alnylam Collaborate for NASH Research Program

    On March 21, Regeneron (REGN) and Alnylam Pharmaceuticals (ALNY) announced that the companies had formed a collaboration to develop innovative RNAi therapeutics targeting NASH and other liver conditions. The companies plan to combine Regeneron’s research based on the role of a variant of the HSD17B13 gene in reducing the risk of NASH with Alnylam’s RNAi capabilities of targeting and silencing specific genes.

  • How Regeneron Stock Performed in the First Half of October
    Market Realist2 days ago

    How Regeneron Stock Performed in the First Half of October

    On October 15, Regeneron (REGN) closed at $377.55, which was 1.72% lower than its previous closing price on October 12. On October 15, the company had a market capitalization of $40.08 billion. Regeneron and Sanofi (SNY) are awaiting the FDA’s decision regarding Dupixent in its asthma indication by the Prescription Drug User Fee Act (or PDUFA) date of October 20.

  • Biogen: Revenue Growth Is Expected in Q3
    Market Realist2 days ago

    Biogen: Revenue Growth Is Expected in Q3

    As we discussed in the previous part, analysts expect Biogen’s (BIIB) revenues to increase 8.3% to $3.33 billion during the third quarter. Biogen’s product portfolio includes multiple sclerosis products, spinal muscular atrophy products, biosimilars, and other products. Biogen’s portfolio also includes Anti-CD20 therapeutic programs.

  • PR Newswire2 days ago

    Kevzara® (sarilumab) Data at the 2018 ACR/ARHP Annual Meeting Provide Additional Insight on Safety and Efficacy in Rheumatoid Arthritis

    TARRYTOWN, N.Y. and BRIDGEWATER, N.J., Oct. 19, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will present data from analyses of the Kevzara® (sarilumab) Phase 3 clinical development program at the 2018 ACR/ARHP Annual Meeting, which is being held in Chicago from October 19 to 24. A late-breaking poster presentation will discuss new post-hoc analyses from the positive Phase 3 MONARCH and MOBILITY RA trials, which have previously reported results showing Kevzara significantly improved efficacy over two commonly-used RA therapies. The new analyses show patients with high baseline levels of interleukin-6 (IL-6) had higher disease activity and joint damage at baseline and showed a greater response to Kevzara 200 mg compared to either methotrexate (MTX) alone or adalimumab than patients with low IL-6 levels.

  • Why the Earnings Surprise Streak Could Continue for Regeneron (REGN)
    Zacks3 days ago

    Why the Earnings Surprise Streak Could Continue for Regeneron (REGN)

    Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Regeneron's Dupixent Meets Goals in Nasal Polyps Studies
    Zacks4 days ago

    Regeneron's Dupixent Meets Goals in Nasal Polyps Studies

    Regeneron's (REGN) atopic dermatitis drug, Dupixent meets goals in two late-stage studies for nasal polyps.

  • 4 Strong Stocks to Buy That Double As Big Takeover Targets
    InvestorPlace5 days ago

    4 Strong Stocks to Buy That Double As Big Takeover Targets

    One of the quickest ways to make money in the stock market is through M&A. Acquisition premiums are usually in excess of 20%, so if you own stock in a company and that company gets acquired, you could easily make 20% or more in a day. The potential rewards from takeover stocks are compelling.

  • PR Newswire5 days ago

    Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

    PARIS and TARRYTOWN, N.Y., Oct. 16, 2018 /PRNewswire/ -- Two pivotal Phase 3 placebo-controlled trials evaluating Dupixent® (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps ("CRSwNP") met all primary and secondary endpoints.

  • Reuters5 days ago

    Sanofi, Regeneron say late-stage Dupixent trials show positive results

    Drugmakers Sanofi and Regeneron said on Tuesday that they received positive results for their Dupixent product, which treats eczema and is seen as a key driver of future revenues. Sanofi and Regeneron ...

  • GlobeNewswire5 days ago

    Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

    Dupixent ® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps Dupixent significantly reduced nasal polyp size, nasal congestion ...

  • PR Newswire5 days ago

    Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that both pivotal Phase 3 placebo-controlled trials evaluating Dupixent® (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps ("CRSwNP"), met all their primary and secondary endpoints.

  • 5 Healthcare Stocks to Buy for Complete Portfolio Wellness
    InvestorPlace11 days ago

    5 Healthcare Stocks to Buy for Complete Portfolio Wellness

    Figuring out which healthcare stocks to buy has never been an easy task. President Trump has repeatedly blasted the Affordable Care Act, promising to overhaul our healthcare system. Naturally, many healthcare stocks have experienced a tumultuous ride in the markets under the Trump White House.

  • How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support
    Investor's Business Daily12 days ago

    How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support

    The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.

  • InvestorPlace12 days ago

    ARWR Stock Sinks After Signing a Big Collaboration Deal

    On the charts, Arrowhead Pharmaceuticals (NASDAQ: ARWR) showed a “double top,” touching around $20 twice between September and October, before crashing down more than 30% in the last week. As value investors will ask after such a drop…what happened? On Oct. 4, Arrowhead announced that it entered into a license and collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ).

  • PR Newswire12 days ago

    Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation

    TARRYTOWN, N.Y. and PARIS, Oct. 8, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi will present a diverse set of data from their joint clinical program investigating Libtayo® (cemiplimab-rwlc) at the ESMO 2018 Congress (European Society for Medical Oncology) from October 19 to 23 in Munich, Germany. Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1).

  • 3 Top Biotech Stocks to Buy in October
    Motley Fool12 days ago

    3 Top Biotech Stocks to Buy in October

    Adding these biotech stocks to growth portfolios this month could prove to be profit-friendly.

  • PR Newswire13 days ago

    Regeneron to Report Third Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2018

    TARRYTOWN, N.Y. , Oct. 8, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2018 financial and operating results on Tuesday, November ...

  • Simply Wall St.16 days ago

    Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Financial Strength Analysis

    With a market capitalization of US$43.5b, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is a large-cap stock, which is considered by most investors as a safe bet. Common characteristics for these big stocks Read More...

  • Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
    Zacks18 days ago

    Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs

    The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.

  • Ionis Pharmaceuticals’ Valuations on September 28
    Market Realist18 days ago

    Ionis Pharmaceuticals’ Valuations on September 28

    Ionis Pharmaceuticals (IONS) develops drugs for life-threatening diseases, and it commercializes the approved products in collaboration with other pharmaceutical companies. Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in YoY (year-over-year) revenues compared to the second quarter of 2017.